Merus
As of the edition of 20 October 2026, Merus runs 29 drugs, 3 of them marketed; it is on route A at 4 targets and on route B at 13 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 6 company names in this family.
- Merus B.V.: acquired in 2025; successor Genmab A/S
- Merus NV: acquired in 2025; successor Genmab A/S
Drugs by status
| Status | Count |
|---|---|
| Marketed | 3 |
| Active | 10 |
| Went quiet | 1 |
| Stopped | 12 |
| Status not established | 3 |
| Total | 29 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Epcoritamab | Ends 2035 (computed from the first US licence) | 2 |
| Tisotumab vedotin | Ends 2033 (computed from the first US licence) | 11 |
| Zenocutuzumab | Ends 2036 (computed from the first US licence) | 2 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 4 targets, route B at 13 targets.
All 17 rows on route A or B
In the product17 company-target rows on route A or B; 14 are not shown here, and no score is.
See all 17 targets where Merus needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 61 trials led
- Blood and lymph: 24 trials led
- Immune system: 24 trials led